Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Revier Therapeutics secures €6 million in seed financing, led by KHAN Technology Transfer Fund II, to develop innovative therapies for cardiometabolic disease.

PRIVATEAug 25, 2026•about 4 hours ago

Amount Raised

€6 Million

Round Type

Seed

HeidelbergBiotechnologyHealth CareTherapeutics

Investors

Private Investors Through Revier Invest HeidelbergVor NvcHigh Tech GründerfondsKhan Technology Transfer Fund Ii

Description

Revier Therapeutics has announced the closing of €6 million in seed financing to pioneer class IIa histone deacetylases for treating cardiometabolic diseases. The funding will enhance the company's pipeline, focusing on heart failure and cardiovascular disease. This financing was supported by multiple investors, including KHAN Technology Transfer Fund II. The company's mission is to deliver impactful and long-term solutions for patients.

Company Information

Company

Revier Therapeutics

Location

Heidelberg, Baden Württemberg, Germany

About

Revier Therapeutics has established the first therapeutic approach to selectively target Class IIa HDACs for the treatment of cardiometabolic diseases. The company's orally available small molecules aim to inhibit pathogenic enzymatic activity while preserving healthy biological function. This innovative strategy is designed to provide impactful and long-term solutions for patients with conditions such as heart failure and atherosclerotic cardiovascular disease. Revier is advancing a pipeline of novel disease modulators with the goal of reshaping the standard of care.

Don't miss Revier Therapeutics's next move

Get an email the moment Revier Therapeutics raises, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for Revier Therapeutics's next move

Learn about Strategic plan

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Revier Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.